Restenosis after coronary angioplasty - A review of the pathogenesis and strategies for prevention
dc.contributor.author | Davids, MR | |
dc.contributor.author | Doubell A.F. | |
dc.date.accessioned | 2011-05-15T16:15:59Z | |
dc.date.available | 2011-05-15T16:15:59Z | |
dc.date.issued | 1995 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Review | |
dc.identifier.citation | Cardiovascular Journal of Southern Africa | |
dc.identifier.citation | 6 | |
dc.identifier.citation | 3 | |
dc.identifier.issn | 10159657 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/13579 | |
dc.subject | abciximab | |
dc.subject | acetylsalicylic acid | |
dc.subject | amiloride | |
dc.subject | angiopeptin | |
dc.subject | anticoagulant agent | |
dc.subject | antisense oligonucleotide | |
dc.subject | arginine | |
dc.subject | beta adrenergic receptor blocking agent | |
dc.subject | carvedilol | |
dc.subject | cilazapril | |
dc.subject | corticosteroid | |
dc.subject | cyclosporin A | |
dc.subject | diltiazem | |
dc.subject | dipyridamole | |
dc.subject | eptifibatide | |
dc.subject | fish oil | |
dc.subject | heparin | |
dc.subject | hirudin | |
dc.subject | hirulog | |
dc.subject | ketanserin | |
dc.subject | losartan | |
dc.subject | low molecular weight heparin | |
dc.subject | mevinolin | |
dc.subject | monoclonal antibody | |
dc.subject | probucol | |
dc.subject | prostacyclin | |
dc.subject | sulfinpyrazone | |
dc.subject | trapidil | |
dc.subject | urokinase | |
dc.subject | coronary artery obstruction | |
dc.subject | endothelium | |
dc.subject | human | |
dc.subject | intraarterial drug administration | |
dc.subject | pathogenesis | |
dc.subject | review | |
dc.subject | thrombosis | |
dc.subject | transluminal coronary angioplasty | |
dc.title | Restenosis after coronary angioplasty - A review of the pathogenesis and strategies for prevention | |
dc.type | Review |